ALIM - Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines
- Sinopharm, China's large state-owned pharma, will transfer six of its vaccine companies to Beijing Tiantan Biological Products, a Shanghai-listed biopharma that is 50% owned by Sinopharm.
- Shanghai's SciNeuro Pharma in-licensed Greater China rights to Lilly's alpha-synuclein targeted antibody therapies, an expected therapy for Parkinson's.
- Gracell Biotech, a Suzhou cell therapy company, reported positive results from a China Phase I trial of its allogeneic CAR-T candidate.
For further details see:
Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines